Margaret Webb, MD
Hospitalist · Jacksonville, FLNPI 1962847384
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,253 of the $3,637 with a category attached, or 89.4%. It is spread thinly across 31 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,615, 7.6 times the $213 reported in 2019. Among hospitalist clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$551
- Novartis$526
- Johnson & Johnson$433
- Regeneron Healthcare Solutions, Inc.$404
- LEO Pharma Inc.$235
- Sanofi$171
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,25389%
- Education$38411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $551 |
| Novartis | 23 | $526 |
| Johnson & Johnson(2 entities) | 17 | $433 |
| Regeneron Healthcare Solutions, Inc. | 10 | $404 |
| LEO Pharma Inc. | 10 | $235 |
| Sanofi | 2 | $171 |
| Incyte Corporation | 1 | $126 |
| Mallinckrodt Hospital Products Inc. | 4 | $109 |
| Amryt Pharma Holdings Ltd | 1 | $106 |
| Organon | 7 | $93 |
| Amgen | 5 | $92 |
| Pfizer | 6 | $92 |
| E.r. Squibb & Sons, L.L.C. | 5 | $78 |
| Lilly USA, LLC | 4 | $72 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $67 |
| VYNE Pharmaceuticals Inc. | 2 | $50 |
| Sun Pharmaceutical Industries Inc. | 2 | $49 |
| Melinta Therapeutics, LLC | 3 | $48 |
| Kyowa Kirin, Inc. | 2 | $37 |
| Galderma Laboratories, L.p. | 2 | $36 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $34 |
| Convatec Inc. | 1 | $33 |
| AstraZeneca | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $28 |
| UCB, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Seagen Inc. | 1 | $21 |
| Arcutis Biotherapeutics, Inc. | 1 | $20 |
| Almirall LLC | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $18 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,637 in reported general payments places this provider in the 95th percentile of 1,570 hospitalist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RemicadeInfliximab | 15 | $182,180 |
| OpzeluraRuxolitinib Phosphate | 13 | $25,127 |
| Tacrolimus | 21 | $2,447 |
| Triamcinolone Acetonide | 84 | $1,478 |
| Ketoconazole | 73 | $1,376 |
| CiclopiroxCiclopirox Olamine | 24 | $693 |
| Fluorouracil | 11 | $660 |
| Clobetasol Propionate | 14 | $648 |
| Clindamycin Phosphate | 12 | $609 |
| Doxycycline Hyclate | 26 | $251 |
| Mupirocin | 20 | $119 |
| Hydrocortisone | 19 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonRemicade | $433 | $182,18015 claims |
| Incyte CorporationOpzelura | $126 | $25,12713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,570 hospitalist providers in Florida.
Other hospitalist in Jacksonville
- Carlos RojasJacksonville$6K
- Anil SuryaprasadJacksonville$4K
- Jeffrey GarlandJacksonville$3K
- David ShupeJacksonville$3K
- Deepak ScindiaJacksonville$2K
- Murray EpsteinMiami$370K
- Oliver AbelaFort Myers$77K
- Joshua LenchusFort Lauderdale$73K
- Tuncay TaskesenThe Villages$22K
- Diego MunozApopka$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.